Compare VFC & PRAX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | VFC | PRAX |
|---|---|---|
| Founded | 1899 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Apparel | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.4B | 9.6B |
| IPO Year | 1994 | 2020 |
| Metric | VFC | PRAX |
|---|---|---|
| Price | $18.76 | $330.00 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 17 | 15 |
| Target Price | $17.56 | ★ $572.13 |
| AVG Volume (30 Days) | ★ 5.8M | 364.5K |
| Earning Date | 04-28-2026 | 05-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 80.72 | N/A |
| EPS | ★ 0.95 | N/A |
| Revenue | ★ $10,488,556,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $2.06 | $6,395.88 |
| P/E Ratio | $19.82 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.41 | $26.70 |
| 52 Week High | $23.90 | $354.87 |
| Indicator | VFC | PRAX |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 53.52 |
| Support Level | $18.05 | $290.36 |
| Resistance Level | $20.40 | N/A |
| Average True Range (ATR) | 0.90 | 18.34 |
| MACD | -0.25 | -2.56 |
| Stochastic Oscillator | 24.76 | 57.24 |
VF designs, produces, and distributes branded apparel, footwear, and accessories. Its apparel categories are active, outdoor, and work. Its portfolio of 10 brands includes Vans, The North Face, Timberland, and Altra. VF markets its products in the Americas, Europe, and Asia-Pacific through wholesale sales to retailers, e-commerce, and branded stores owned by the company and partners. Tracing its roots to 1899, the company has evolved through many brand acquisitions and dispositions.
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.